PocketEdge
← All news

Desk note · industry · Healthcare manufacturing / industrial policy

India extended medical-device subsidies toward parts, not just finished kits

On 10 November 2026 the Department of Pharmaceuticals reopened the Production Linked Incentive scheme for medical devices through 2035-36 with about ₹2,700 crore of outlay, shifting PLI 2.0 toward critical components and high-end equipment as industry bodies warned device imports could cross ₹1 lakh crore this year.

10 Nov 2026 · 2 min read

Key takeaways

  • •Fresh applications under medical-device PLI 2.0 opened on 10 November 2026 with manufacturing incentives spread across consumables, critical components, advanced imaging gear, and equipment that is today only assembled domestically.
  • •The revised programme removes minimum sales thresholds for claiming incentives, allows three years to commission projects, and offers differentiated rates where domestic capacity is thinnest.
  • •Association of Indian Medical Device Industry coordinator Rajiv Nath said imports could exceed ₹1 lakh crore in 2026, making local component capacity a policy priority.

What's going on here?

Hospitals buy devices every week, but much of the bill still lands on imports when domestic plants only screw together foreign kits. On 10 November 2026, the Department of Pharmaceuticals invited new applications under an expanded Production Linked Incentive scheme for medical devices, extending support through 2035-36 with an outlay of about ₹2,700 crore. PLI 2.0 splits the money across four buckets: everyday consumables and implants, critical components, high-end machines where local manufacturing is still nascent, and equipment that today reaches Indian plants mainly as an assembly line. The government said the first phase since FY21 had already enabled production of more than 60 categories, including MRI systems, CT scanners, cath labs, and dialysis lines worth over ₹16,000 crore of output. Industry forums welcomed the reboot but stressed that the earlier version left gaps on components and shop-floor scale.

What does this mean?

Incentives now follow where import bills hurt most. Finished device lines got attention in PLI 1.0; version 2.0 tilts toward syringes, probes, and precision parts that hospitals reorder constantly. Longer implementation windows and no minimum sales hurdle lower the entry bar for mid-sized Indian manufacturers and for global firms willing to localise deeper than a single assembly hall. Poly Medicure managing director Himanshu Baid, quoted in the same reporting cycle, said differentiated rates match how hard each segment is to build. Higher support where import dependence is deepest can nudge capital toward tool rooms and sterile packaging, not only finished machines. Procurement rules, tariff bands, and a dedicated medtech regulator still matter as much as cash rebates, but the subsidy map now signals components first.

Why should I care?

Hospital procurement managers should track which domestic vendors qualify for PLI 2.0 before the next bulk tender, because accredited local lines can shorten spare-part lead times. Medtech entrepreneurs weighing a factory bet get a clearer list of eligible segments and timelines. Investors in listed device makers should read annual reports for capex tied to component lines, not only assembly margin. Watch how many applications file by the first compliance window, whether AiMeD and MTaI push for faster customs and procurement preference, and if import statistics for the December quarter show any early shift away from China and Vietnam on disposables.

More desk notes

Disclaimer

For informational purposes only. Not investment advice. Verify with filings and a licensed adviser.